跳至主要内容
临床试验/NCT00282217
NCT00282217已完成4 期

Sirolimus in the Treatment of Histological Defined Chronic Allograft Nephropathy

Wyeth is now a wholly owned subsidiary of Pfizer13 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2006年8月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
100
试验地点
13
主要终点
Renal function at 12 months; Comparison between slopes of glomerular filtration rate (GFR) of one year before versus one year after start on sirolimus

研究概览

简要总结

The aim of this study is to test whether withdrawal of calcineurin inhibitors, followed by treatment with sirolimus, may improve renal function in renal transplant recipients with chronic allograft nephropathy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Renal transplantation
  • Biopsy-confirmed chronic rejection
  • Treatment with mofetil mycophenolate among cyclosporine or tacrolimus

排除标准

  • Transplant of any organ other than the kidney
  • Current important infection
  • Acute rejection within 12 weeks prior to inclusion

结局指标

主要结局

Renal function at 12 months; Comparison between slopes of glomerular filtration rate (GFR) of one year before versus one year after start on sirolimus

次要结局

  • Histological parameters at 12 months
  • Cumulative incidence of biopsy-confirmed acute rejection at 12 months
  • Effect at 12 months on proteinuria, blood pressure, hyperlipidemia, and proteinuria

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

研究点 (13)

Loading locations...

相似试验

Study Evaluating Sirolimus in the Treatment of... | 临床试验